Abstract
The PrP propensity to adopt different structures is tightly linked to transmissible spongiform encephalopathies (TSE) which include Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scjeinker (GSS) and Kuru syndrome. In most cases, TSE is associated with the accumulation in the brain of an abnormally folded protease-resistant protein, PrPSc or PrPres, which is derived from a cellular host-encoded protease-sensitive conformer, designated PrPC. The prion propagation in the brain is postulated to occur via a conformational change of PrPC into the amyloidogenic form PrPSc, characterized by a high β sheet content. The characterization of PrPSC oligomers as well as their biological activity is currently an area of active research. Indeed, PrPSc structural diversity was proposed several years ago as a hypothesis to explain the origin of “prion strain” diversity. As prion pathologies belong to protein miss-assembly diseases, investigation of PrP conformational dynamics and, more precisely, oligomerization pathways exploration will help to acheave a better understanding of the pathological events at the molecular level.
Keywords: transmissible spongiform encephalopathies, kinetic intermediate, oligomerization, soluble oligomers, protein misassembly, amyloid, catalyse, nucleus, seed
Current Alzheimer Research
Title: Prion Protein Oligomerization
Volume: 5 Issue: 6
Author(s): H. Rezaei
Affiliation:
Keywords: transmissible spongiform encephalopathies, kinetic intermediate, oligomerization, soluble oligomers, protein misassembly, amyloid, catalyse, nucleus, seed
Abstract: The PrP propensity to adopt different structures is tightly linked to transmissible spongiform encephalopathies (TSE) which include Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scjeinker (GSS) and Kuru syndrome. In most cases, TSE is associated with the accumulation in the brain of an abnormally folded protease-resistant protein, PrPSc or PrPres, which is derived from a cellular host-encoded protease-sensitive conformer, designated PrPC. The prion propagation in the brain is postulated to occur via a conformational change of PrPC into the amyloidogenic form PrPSc, characterized by a high β sheet content. The characterization of PrPSC oligomers as well as their biological activity is currently an area of active research. Indeed, PrPSc structural diversity was proposed several years ago as a hypothesis to explain the origin of “prion strain” diversity. As prion pathologies belong to protein miss-assembly diseases, investigation of PrP conformational dynamics and, more precisely, oligomerization pathways exploration will help to acheave a better understanding of the pathological events at the molecular level.
Export Options
About this article
Cite this article as:
Rezaei H., Prion Protein Oligomerization, Current Alzheimer Research 2008; 5 (6) . https://dx.doi.org/10.2174/156720508786898497
DOI https://dx.doi.org/10.2174/156720508786898497 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion
Current Cancer Drug Targets Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Effects of Vitamin A Deficiency and Opioids on Parvalbumin + Interneurons in the Hippocampus of the HIV-1 Transgenic Rat
Current HIV Research The Metabolite Trimethylamine-N-Oxide is an Emergent Biomarker of Human Health
Current Medicinal Chemistry Dangerous Liaisons between Beta-Amyloid and Cholinergic Neurotransmission
Current Pharmaceutical Design Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Current Pharmaceutical Design Biological and Genetic Features of Neuroblastoma and Their Clinical Importance
Current Pediatric Reviews Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer’s Disease
Current Drug Targets Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Hepatic MicroRNA Orchestra: A New Diagnostic, Prognostic and Theranostic Tool for Hepatocarcinogenesis
Mini-Reviews in Medicinal Chemistry Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents Delivery Systems for Birch-bark Triterpenoids and their Derivatives in Anticancer Research
Current Medicinal Chemistry Non-Analgesic Effects of Opioids: Neuroprotection in the Retina
Current Pharmaceutical Design